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ABSTRACT (250 words) 1 
Background: Constipation is a prevalent gastrointestinal disorder. Patient dissatisfaction with prescribed 2 
medications is common, and there is need for alternative management strategies. Evidence shows that 3 
Bifidobacterium species may be beneficial in constipation.  4 
Aim: To investigate changes in physiological and clinical measures of gut function in patients with chronic 5 
constipation following the consumption of Bifidobacterium lactis NCC2818, compared to placebo. 6 
Methods: Participants were randomised to a 4 week supplementation with B. lactis NCC2818 or placebo. 7 
Gut transit time was measured using the radio-opaque marker technique, while symptoms and quality of 8 
life were assessed using validated questionnaires. Gut microbiota composition was assessed using 9 
quantitative polymerase chain reaction. Analysis of covariance was used for normally distributed 10 
variables, and Mann-Witney test for non-normally distributed variables. 11 
Results: Seventy five participants were randomised. There was no significant difference between the 12 
probiotic and placebo groups in gut transit time change from baseline to week 2 (-11.7 h, SD 33.0 h vs -13 
12.9 h, SD 33.6 h; p=0.863) or to week 4 (-20.4 h, SD 32.5 h vs -8.7 h, SD 33.8 h; p=0.103). There were also 14 
no improvements in stool output, symptoms or quality of life. No differences were found in 15 
Bifidobacterium concentrations between the probiotic and placebo groups at week 4 (9.5 log10/g dry 16 
faeces, SD 0.3 vs 9.4 log10/g, SD 1.0; p=0.509). 17 
Conclusions: B. lactis NCC2818 was not effective in the management of mild chronic constipation. This 18 
study highlights the importance of further studies and their publication to better understand the strain-19 
specific effects of probiotics.  20 
 21 
 22 
 23 
  24 
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INTRODUCTION 1 
Constipation is a common burdensome functional bowel disorder in which symptoms of difficult, 2 
infrequent, or incomplete defecation predominate 1. Management remains challenging, with constipation 3 
representing a significant healthcare burden costing up to $7,522 per year per patient 2. Despite the range 4 
of treatments available including laxatives and fiber supplements, approximately half of patients are 5 
dissatisfied with current management strategies, with the main complaint relating to limited efficacy 3. 6 
Hence, there is an unmet need for alternative treatments for the management of constipation-related 7 
symptoms. 8 
Probiotics are "live microorganisms that, when administered in adequate amounts, confer a health benefit 9 
to the host” 4. In the past decade, research has focused on their effectiveness in chronic constipation, 10 
possibly mediated through an effect on regulating gut dysmotility by impacting the gut microbiota, with 11 
the subsequent release of metabolites, including short-chain fatty acids (SCFA) during fermentation 5-7, 12 
that are known to interact with the enteric nervous system and the immune system 5. 13 
A systematic review and meta-analysis revealed 14 RCTs investigated the effect of probiotics in adults 14 
with chronic constipation 8; this suggested that probiotics may improve whole gut transit time (WGTT), 15 
stool frequency and stool consistency, with sub-group analysis based upon species indicating significant 16 
effects in favour of Bifidobacterium lactis 8. However, despite favourable results reported, the clinical 17 
importance of probiotics in constipation remains uncertain, due to small study sample sizes, high 18 
heterogeneity in the study design of the individual studies, and limitations in study methodologies, 19 
including the use of non-validated assessment tools. Nevertheless, the promising findings of the meta-20 
analysis, justify further research to identify B. lactis strains that may be effective in the management of 21 
chronic constipation.  22 
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Therefore, the aim of this study was to investigate changes in gut transit time and gastrointestinal 1 
symptoms following 4 weeks consumption of a probiotic strain in a randomized, double-blind, placebo-2 
controlled manner, in adults with constipation. 3 
MATERIAL AND METHODS  4 
Protocol 5 
The study was a randomized, parallel-group, double-blind, placebo-controlled, adaptive randomised 6 
controlled trial (RCT). The intervention period was four weeks, while the primary outcome (change in 7 
WGTT) was assessed at week 2 (i.e. mid-intervention). Participants were recruited from the community 8 
and were required to attend five study visits: the screening visit, where informed consent was taken, 9 
inclusion/exclusion criteria assessed, and eligible participants enrolled to the study; the baseline visit, 10 
where final eligibility tests and randomisation were undertaken, and assessment of clinical, physiological 11 
and stool microbiological outcomes were performed; the mid-intervention (week 2) and end of 12 
intervention (week 4) visits, where assessment of clinical, physiological and stool microbiological 13 
outcomes were also performed; and the follow-up (week 8) visit, where evaluation of clinical outcomes 14 
was performed. The trial took place within Queen Mary University of London from January 2014 to 15 
October 2015. 16 
Participants 17 
Adults from the general population with mild constipation were enrolled to this study. Inclusion criteria 18 
were: 18-65 years old; self-reported stool frequency of 3 or less bowel movements per week; self-19 
reported stool consistency of type 1-4 on the Bristol Stool Form Scale; fulfilment of modified Rome III 20 
diagnostic criteria for functional constipation 9; mild constipation determined using a score of 8-15 on the 21 
Cleveland Clinic Constipation Score (CCCS: max score = 30) 10; body mass index (BMI) of 18.5-29.9 kg/m2, 22 
and willingness to use effective contraception for the duration of the trial (for females only). 23 
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Exclusion criteria were: gastrointestinal, neurological, cardiovascular, endocrine, renal or other chronic 1 
diseases likely to affect gut motility; prior abdominal surgery; ongoing therapy with medications known 2 
to affect gut motility; alarm features and moderate or severe anorectal problems; lactose intolerance, 3 
cow’s milk allergy and soya allergy; regular consumption of probiotics, prebiotics, fiber supplements and 4 
laxatives; use of antibiotic within 4 weeks of study onset; high fibre intake, defined as >18 g/d assessed 5 
using the Block Fibre Screener 11; high anxiety and depression score defined as a score >11 on the Hospital 6 
Anxiety and Depression Score (HADS) questionnaire, and ongoing alcohol, drug or medication abuse. At 7 
the baseline visit and prior to randomization, participants with short whole gut transit time (WGTT), 8 
defined as <24 h measured using radio-opaque markers were also excluded, as were participants 9 
reporting being ‘markedly better’ between screening and baseline (score +3 on the Global Constipation 10 
Symptom Score at baseline visit). 11 
Randomization, blinding and study products  12 
After fulfilling eligibility criteria at the baseline visit, participants were randomly allocated to either the 13 
probiotic or placebo. Dynamic allocation (minimisation) was chosen, and randomisation was performed 14 
through Medidata Balance (www.imedidata.com) by the study team at baseline visit. The latter was set-15 
up independently and was not accessible by the study site staff except when receiving an allocation 16 
assignment for a specific patient at the baseline visit, ensuring allocation concealment. Randomisation 17 
was stratified by gender and, for females, by menstrual cycle phase at baseline (mid-follicular/mid-18 
luteal/post-menopausal), as both have been shown to influence WGTT 12 13. Once randomisation was 19 
performed online, Medidata Balance would display the product code (PrXXX) the participant had been 20 
allocated to. Patients and investigators were blinded to the treatment allocation and blinding was 21 
maintained until the end of the data analysis.  22 
The probiotic group received spray-dried B. lactis NCC2818 at a dose of 1.5 x 1010 CFU/d, with a minimum 23 
end of shelf-life count of 8 x 109 CFU/d, while the placebo received maltodextrin powder. The study 24 
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products were supplied by Nestlé (Switzerland) in a milk powder-based format and packaged in aluminium 1 
sachet sticks, with each stick containing 24 g of powder. The base composition of the study products was 2 
matched and final B. lactis and placebo products were indistinguishable in terms of appearance, colour, 3 
texture and flavour. Participants were instructed to consume the contents of one stick mixed with 200 ml 4 
of water each day for 4 weeks. All study products were refrigerated (4-8oC) both at the study site and by 5 
the participants throughout the intervention period. Viability of the probiotic in sachets was assessed and 6 
confirmed during and at the end of the study by Nestlé. 7 
 8 
Clinical outcomes 9 
The primary outcome was change in WGTT after 2 weeks (i.e. baseline vs mid-intervention) between 10 
probiotic and placebo. The secondary clinical outcomes included stool output, constipation symptoms and 11 
severity, and constipation-related quality of life. Palatability and compliance with the study product, as 12 
well as dietary intake, physical activity, and anxiety and depression, were also assessed. 13 
Whole gut transit time 14 
Whole and regional gut transit times were assessed using a standard radio-opaque markers (ROM) 15 
technique 14. Participants were provided with a box containing 12 capsules, each containing 6 ring markers 16 
(PRODIMED®, Plastimed, France). Participants ingested two capsules per day (total of 12 ROM per day) 17 
for six consecutive days prior to the baseline, mid-intervention and end of intervention visit. On the 18 
seventh day (study visit day), an abdominal x-ray was performed to determine location of any retained 19 
markers from which both regional and WGTT could be calculated.  20 
Stool output, constipation outcomes and gut symptoms 21 
Stool frequency and stool consistency were assessed using a daily stool diary and the Bristol Stool Form 22 
Scale 15, respectively, throughout the study. The total number of bowel movements (TBM), the number 23 
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of spontaneous bowel movements (SBM), and the number of complete spontaneous bowel movements 1 
were calculated based on the averages over the seven days prior to the baseline, mid-intervention and 2 
end-of-intervention visits. 3 
Participants were also required to complete the validated CCCS 10, Patient Assessment of Constipation 4 
Symptoms (PAC-SYM) 16, and Patient Assessment of Constipation Quality of Life (PAC-QoL) 17 at each study 5 
visit. In addition, the Global Constipation Symptom Score (GCSS) was completed at all visits except for the 6 
screening visit, to assess current symptom severity compared to those experienced at baseline on a scale 7 
from -3 (markedly worse) to +3 (markedly better) 16. Both PAC-SYM and PAC-QoL were used to define 8 
responders from non-responders. A reduction of ≥1 point in PAC-SYM or PAC-QoL score was considered 9 
a minimal clinically important difference 17 18.  10 
Bloating was assessed at all visits other than the screening visit using a 100 mm visual analogue scale (VAS) 11 
anchored by the word descriptions “not at all” and “all the time” at each end. A number of GI symptoms 12 
were also measured in order to assess tolerance of the study product (abdominal discomfort, abdominal 13 
bloating/distention, flatulence, nausea) by means of a composite GI tolerance score, 6 days after the start 14 
of product consumption, and at the end of the intervention period. Participants were asked to rate the 15 
frequency and severity of these symptoms on a 5-point Likert scale ranging from 0 (absent) to 4 (very 16 
severe) over the past 24 h, as well as over the past 6 days 19 20. Responses to the questions were used to 17 
calculate a mean GI tolerance score for each visit using the following formula: 18 
Mean GI tolerance score =
Sum of (response to individual question x corresponding frequency)
Sum of frequency for all answered questions
 19 
Palatability and compliance 20 
Palatability of the study product was assessed 6 days after baseline and at the end of intervention visit 21 
using a VAS anchored by the word descriptors “worst” and “best” at each end. Diaries were completed 22 
every day during the 4 week intervention period to report intake, and hence compliance, of the 23 
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probiotic/placebo. Non-compliance was defined a priori in the following three ways: (a) participants with 1 
>2 consecutive days without any probiotic/placebo intake during the first two weeks of the intervention 2 
period (i.e. between baseline and mid-intervention visits); or (b) >3 consecutive days without 3 
probiotic/placebo intake during the last two weeks of the consumption period (i.e. between mid and end 4 
of intervention visits); or (c) no probiotic/placebo consumption on all 3 days prior to mid-intervention visit 5 
or end of intervention visit. 6 
Confounding factors 7 
A three day unweighed food and drink diary was completed prior to each study visit to assess dietary 8 
intake. Food diaries were analysed for nutritional composition using the Nutritics Professional Nutrition 9 
Analysis software (Nutritics v3.74, Ireland). Physical activity was also measured at each study visit using 10 
the validated International Physical Activity Questionnaire (IPAQ) 21. Anxiety and depression were 11 
assessed at each visit via the HADS questionnaire which contains two subscales, with seven items for 12 
anxiety (HADS-A) and seven for depression (HADS-D) 22.  13 
Microbiological outcomes 14 
One fresh stool sample was collected at baseline, mid-intervention (week 2) and end of the intervention 15 
(week 4) from each participant and used for microbiological analysis. Participants were provided with a 16 
bespoke stool collection kit and were instructed to provide a fresh stool sample at the next scheduled visit 17 
or at a convenient time within 5 days from the scheduled study visit. The stool sample had to be returned 18 
to the study site no more than 3 hours following defaecation. Participants were instructed to store the 19 
fresh stool sample in a Styrofoam box with frozen gel packs (provided by the researchers) to preserve the 20 
sample in a cold temperature and minimise loss of cell viability 23. Stool sample collection was an optional 21 
task for participants in order to reduce the burden of study participation; hence microbiology data were 22 
not available for all participants. 23 
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Quantitative polymerase chain reaction (qPCR) was used to quantify the gut microbiota in this study from 1 
phylum to species level. Fresh stool was diluted 1:3 with sterile phosphate buffered saline/30% glycerol 2 
buffer, homogenised and frozen at 80 °C until analysis. DNA extraction was performed using the FastDNA 3 
SPIN Kit for Soil (MP Biomedicals Europe, Illkirch, France). The reporter system used was SYBR Green 4 
Supermix (Biorad, California, USA), and primers were purchased for the following assays: universal 5 
bacteria, Lachnospiraceae, Roseburia spp. (includes Eubacterium rectale), Faecalibacterium prausnitzii, 6 
Bacteroides spp., Prevotella spp., Bifidobacterium spp. and Archaea (Sigma-Aldrich Company Ltd, Dorset, 7 
UK) (Supplementary Material). These target bacterial groups were selected based on bacterial groups and 8 
species that have been previously shown to either be different between healthy and constipated 9 
populations or to be affected by the consumption of probiotics 5. Standards were provided by the Rowett 10 
Institute, University of Aberdeen, UK. 11 
Stool SCFA were quantified using gas-liquid chromatrography (9890A System, Agilent Technology, 12 
California, USA). Stool pH was measured using a pH meter (Seven Compact, Meter Toledo, Leicester, UK) 13 
equipped with a glass electrode specifically designed for slurries (pHRESH Electrode, Beckman Coulter, 14 
High Wycombe, UK). Water content was determined via lyophilisation of frozen samples (LyolabA; LSL 15 
Secfroid SA, Aclens-Lausanne, Switzerland). 16 
Safety outcomes 17 
Adverse events were recorded at each study visit and throughout the study using a pre-specified study 18 
document. All adverse events were summarised according to the System Organ Class (SOC) and Preferred 19 
Term (PT). 20 
Sample size calculation and interim analysis 21 
The study started with two groups (high dose probiotic group vs placebo group), with the plan to perform 22 
an interim analysis that would indicate whether a third, low dose probiotic group was to be included. 23 
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Hence, the sample size calculation was performed for 3 groups and was based on the primary outcome of 1 
change in WGTT at mid-intervention (week 2) in the high dose probiotic group compared to placebo 2 
group, using data from a previously published RCT, in which a mean change in WGTT of -28 h (95% CI -3 
38.9 h to -17.3 h) was observed following probiotic supplementation compared to 1 h (95% CI -5.7 to 8.3) 4 
following placebo 24. Assuming a power of 80% and a 2-sided significance level of 5%, the sample size was 5 
estimated to be 36 participants per group with a total of 108 for all three groups. The attrition was 6 
estimated at 10% leading to an overall sample size of 120 patients across all three groups. 7 
An interim analysis was performed as planned by an independent panel after 39 subjects had completed 8 
the study. Based on the observed effect size and the conditional power, the panel decided that the study 9 
should continue as a two-arm RCT (high dose probiotic vs placebo) with 36 participants per group and a 10 
final sample size of 72.  11 
Statistical analysis 12 
Baseline characteristics of study participants were analysed using mean and SD for continuous variables 13 
and counts and percentages for categorical variables. Continuous variables were assessed for normality 14 
using histograms and Q-Q plots. For normally distributed variables, analysis of covariance (ANCOVA) was 15 
used whereas for non-normally distributed variables Mann-Whitney tests were used. Changes in 16 
outcomes from baseline were compared between groups using an ANCOVA model, with the baseline 17 
measurement as a covariate, and stratification factor (menstrual cycle phase) and study group as fixed 18 
effects. Categorical outcomes were analysed using Chi squared test.  19 
The primary outcome was also analysed using ANCOVA, which had baseline WGTT as a covariate, and 20 
menstrual cycle phase and study group as fixed effects. The alpha (α) spent at interim analysis was 0.0032. 21 
Therefore, to control for multiple comparisons, the α was adjusted for the primary outcome analysis at 22 
α=0.0468. Hence, a P value of <0.0468 was considered statistically significant for the primary outcome. 23 
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The majority of the statistical analysis was performed using SAS® software (version 9.4, North Carolina, 1 
USA) except for the statistical analysis on the absolute values which was performed using IBM SPSS 2 
statistics for Windows (version 22, New York, USA). 3 
All analyses were performed in the intention to treat (ITT) population. For the microbiological outcomes, 4 
the ITT population included all the participants who provided a stool sample for each analysis and for each 5 
study time point. A per-protocol (PP) analysis was performed for the primary outcome analysis only, and 6 
consisted of all participants included in the ITT population who adhered to all protocol requirements 7 
without any major protocol deviations. Missing data were assumed to be missing at random and no 8 
imputation was performed. P values of < 0.05 were considered statistically significant. 9 
Ethical issues 10 
Ethical approval for the study was granted by the Camberwell St Giles NHS Research Ethics Committee 11 
(13/LO/0891). The study was registered at ClinicalTrials.gov (registration number NCT01874301). 12 
 13 
RESULTS 14 
One hundred and seven participants were eligible following screening and enrolled to the study, of whom 15 
75 were randomised and received the study product (probiotic or placebo) (Figure 1).  Demographic and 16 
baseline characteristics of study participants included in the ITT population are summarised in Table 1. 17 
Clinical outcomes 18 
Whole gut transit time 19 
In the ITT population, there was no significant difference in the primary outcome of change in WGTT from 20 
baseline to mid-intervention between the probiotic (-12 h, SD 33 h) and placebo (-13 h, SD 34 h) (p=0.863). 21 
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Similarly, in the PP population, there was no significant difference in the change in WGTT from baseline 1 
to mid-intervention between the probiotic (-11 h, SD 32 h) and the placebo (-17 h, SD 33 h) (p=0.433).  2 
There was no significant difference in change in WGTT from baseline to end of intervention between the 3 
probiotic (-20 h, SD 33 h) and placebo (-9 h, SD 34 h) (p=0.103) (Table 2). There were no significant 4 
differences in WGTT at baseline, mid-intervention or end of intervention between groups, although the 5 
difference at end of intervention approached significance (p=0.062) (Table 2). Regional gut transit time 6 
(left, right and rectosigmoid) were also not significantly different between the groups (Table 2).  7 
No significant difference between the probiotic and placebo groups was shown for the odds of having 8 
WGTT <72 h (i.e. upper limit of normal 25) at mid-intervention (OR 1.8, 95% CI 0.53 -5.0) and end of 9 
intervention (OR 0.8, 95% CI 0.2 -2.7). 10 
Stool output, gut symptoms and constipation outcomes (Table 3) 11 
No significant differences were observed between the probiotic and placebo in the change in total bowel 12 
movements (TBM) from baseline to mid-intervention (p=0.836) and from baseline to end of intervention 13 
(p=0.831). Similarly, no differences were found for spontaneous bowel movements (SBM) and complete 14 
spontaneous bowel movements (CSBM). Furthermore, no significant differences were observed between 15 
the probiotic and placebo groups in the change in stool consistency from baseline to mid-intervention 16 
(p=0.848) and end of intervention (p=0.936). No significant difference was observed for the change from 17 
baseline in GI tolerance or bloating between the groups during the intervention period.  18 
There was no significant difference between the probiotic and placebo groups in the change in PAC-SYM 19 
global score from baseline to mid-intervention (p=0.474), end of intervention (p=0.780) and follow-up 20 
(p=0.907) (Table 4). Similarly, no significant difference was observed between the probiotic and placebo 21 
groups in the change in the abdominal, rectal, and stool sub-scores, at any of the study time points 22 
(Supplementary Table 1). 23 
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In accordance with the lack of difference found for WGTT, stool output and symptom scores, no significant 1 
difference was found between the probiotic and placebo in the change with respect to PAC-QoL global 2 
score from baseline to mid-intervention (p=0.836), end of intervention (p=0.315) and follow-up (p=0.977) 3 
(Table 4). Similarly, no change was observed in the PAC-QoL sub-scores between the two groups at any of 4 
the study time points (Supplementary Table 2). Furthermore, there was no significant difference in the 5 
change from baseline in CCCS and GCSS scores between the probiotic and placebo group at any study time 6 
points (Table 4).  7 
There was no significant difference in the number of responders (defined as a reduction of ≥1 point in 8 
PAC-SYM) between the probiotic and placebo at mid-intervention (n=0 in both groups; p=1.000), end of 9 
intervention (n=2, 5% vs n=2, 5%; p=1.000) and follow-up (n=4, 11% vs n=1, 3%; p=0.356). Similarly, there 10 
was no significant difference in the number of responders (defined as a reduction of ≥1 point in PAC-QoL) 11 
between the probiotic and placebo at mid-intervention (n=1, 3% vs n=0, 0%; p=1.000), end of intervention 12 
(n=1, 3% vs n=0, 0%; p=1.000) and follow-up (n=1, 3% vs n=0, 0%; p=1.000). 13 
Palatability and compliance 14 
At mid-intervention, no significant difference was observed in palatability between the probiotic and 15 
placebo in the ITT population (6.5, SD 4.3 vs 6.3, SD 5.5; p=0.861), nor were there differences at the end 16 
of intervention (6.3, SD 4.3 vs 4.3, SD 6.6) (p=0.107). Thirty-three (89%) participants in the probiotic group 17 
and 35 (92%) in the placebo group complied with the study product intake. 18 
Confounding factors 19 
There was no significant difference in energy, protein, carbohydrate, fibre, and non-starch polysaccharide 20 
intakes between the probiotic and placebo groups at any of the study time points (Supplementary Table 21 
3). There was a significantly higher fat intake at baseline and the end of the intervention (week 4) in the 22 
placebo group compared to the probiotic group (p=0.001 and p=0.036, respectively), although the mean 23 
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difference between the two groups was lower compared to baseline and mid-intervention. However, 1 
when the percentage of energy from fat was calculated, there was no difference between the probiotic 2 
(34%, SD 6%) and placebo (36%, SD 6%) groups at the end of the intervention (p=0.388).  3 
There were no significant differences in physical activity METs between the probiotic and placebo groups 4 
at any of the study time points (Supplementary Table 4). There was also no significant difference in the 5 
change from baseline for the HADS total score, as well as for the anxiety and depression subscale scores, 6 
between the study groups at any of the study time points (Supplementary Material Table 5).  7 
Microbiological outcomes 8 
Fifty-two participants provided stool samples at baseline, 50 at mid-intervention (week 2), and 47 at the 9 
end of intervention (week 4). Forty participants provided a stool sample at each time point, while 61 10 
participant provided stool samples at least at one time point. 11 
There were no significant differences in any of the microbiota measured between the probiotic and 12 
placebo group at baseline, mid- or end of the intervention (Table 5). There were also no significant 13 
differences in any of the SCFA between the probiotic and placebo groups at any of the study time points 14 
(Table 5). Similarly, there were no significant differences in stool pH or water between the probiotic and 15 
placebo groups at any of the study time points (Table 5). 16 
Adverse events 17 
A summary of all the AEs during the study are presented in Supporting Material Table 6. There was no AE 18 
that resulted in interruption or dose reduction of the study product. One participant in the probiotic group 19 
and one in the placebo group experienced serious adverse events that were unrelated to the study 20 
product (trauma caused by car accident and arm fracture). 21 
 22 
 23 
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DISCUSSION 1 
The aim of this trial was to investigate changes in gut transit time and gastrointestinal symptoms following 2 
4 weeks consumption of a probiotic strain in a randomized, double-blind, placebo-controlled manner, in 3 
adults with constipation. 4 
There was no significant difference between the probiotic and placebo in changes in WGTT from baseline 5 
to mid-intervention and end of intervention. These results are unexpected, as a previous study has shown 6 
a significant decrease in WGTT following the consumption of another B. lactis strain, HN019 24. Similarly, 7 
two systematic reviews and meta-analyses - that investigated the effect of various probiotics on WGTT in 8 
healthy and constipated individuals - showed that probiotic consumption significantly decreased WGTT, 9 
with B. lactis strains HN019 and DN-173010 conferring the largest treatment effects, particularly in 10 
constipated individuals compared to healthy people 8 26.  11 
However, it is well known that the effects of probiotics are strain-specific 4. Some actions of probiotics are 12 
common to a range of strains, such as metabolite production 4, whereas others appear to be strain-13 
specific, such as neurological effects 27. The conflicting results between the lack of effect of the B. lactis 14 
NCC2818 strain tested in this study and the beneficial effects shown by other B. lactis strains 28 could be 15 
explained by inter-strain genomic and functional differences, such as immunogenic properties 29 30. As the 16 
immune and nervous systems are key regulators of gut motility, essential to normal gut homeostasis, 17 
different strains may have a variable impact on symptoms of constipation. It is therefore possible that, 18 
although the probiotic strain used in this study has been shown to be effective in another condition like 19 
seasonal allergic rhinitis, via its effect on immunological parameters 31, it has limited impact on gut motility 20 
and hence on constipation.  21 
Interestingly, the effect size of the probiotic on WGTT observed in this study at mid-intervention (i.e. -12 22 
h) is similar to the effect size demonstrated by a meta-analysis of RCTs of probiotics in constipation. 23 
Probiotics were found to significantly reduce WGTT by -12.4 h, with B. lactis HN019 decreasing WGTT by 24 
17 
 
-13.5 h but without reaching significance 8. The sample size calculation for the current trial was based 1 
upon detecting a more relevant 20h- difference effect between the probiotic and placebo (adapted from 2 
Waller et al. 24). In addition, the placebo used in this study also resulted in a similar effect size to the 3 
placebo effect observed in many other studies assessing the effect of probiotics in the management of 4 
lower GI symptoms 32.  5 
Other factors that could have potentially contributed to changes seen in the placebo group were 6 
considered. Firstly, the placebo powder contained maltodextrin, which is a sugar absorbed in the small 7 
intestine and, in theory, in high doses it may be less efficiently absorbed resulting in its colonic 8 
fermentation; however, this has not been previously proven, and maltodextrin has been successfully used 9 
as a placebo in numerous trials in constipation, with a meta-analysis showing no change on WGTT8. 10 
Secondly, physical activity has been associated with changes in gut motility33 34; however, this study 11 
showed no differences in physical activity between groups. Thirdly, there was a significantly higher fat 12 
intake in the placebo group, compared to the probiotic group. Although an association between fat intake 13 
and constipation has been demonstrated35, no studies have conclusively shown a causative effect of fat 14 
in constipation.  15 
The current study also revealed no differences in stool frequency, consistency, GI tolerance, QoL and 16 
constipation-related symptoms (e.g. CCCS, PAC-SYM). These results are in line with the lack of impact on 17 
WGTT, while differing with the findings of the aforementioned meta-analysis, which showed that other B. 18 
lactis strains significantly increased stool frequency by an average of 1.5 bowel movements per week, and 19 
improved stool consistency and other constipation-related symptoms 8. However, methodological 20 
differences between the current and previous studies may account for these findings. For example, Waller 21 
et al., measured weekly stool frequency using a VAS score, instead of completing daily bowel diaries 24. 22 
Furthermore, whereas the current study used the internationally accepted Rome III criteria to diagnose 23 
18 
 
chronic constipation, others have used a variation of less stringent definitions for diagnosing constipation, 1 
e.g. based on stool frequency or WGTT alone 24 36 37.  2 
There are also other factors that could justify the lack of effect seen in the current study. Firstly, this study 3 
was not powered for any of the clinical endpoints and, hence, the sample size may have been too small 4 
to detect a significant difference in the symptoms and quality of life. Secondly, the mean stool frequency 5 
at baseline in both groups (assessed from daily bowel diaries) was more than 3 bowel movements per 6 
week, which is within the range of defaecation frequency for non-constipated people 38. This is probably 7 
due to participants underestimating their stool frequency at screening. Thirdly, only people with mild 8 
constipation, assessed using the CCCS questionnaire (score 8-15), were included in this study. As previous 9 
systematic-reviews and meta-analyses have shown a significantly greater effect of probiotics in 10 
constipated individuals compared to healthy volunteers, the lack of effect of this probiotic could be 11 
potentially due to the presence of only mild constipation symptoms 39. Moreover, a study in IBS has shown 12 
that patients with severe symptoms had the greatest reductions in symptom severity and the largest 13 
improvements in QoL following standard medical treatment, when compared to those with mild or 14 
moderate symptoms 40. Therefore, it is likely that the inclusion of participants with mild constipation could 15 
have limited the potential of B. lactis NCC2818 to reduce constipation-related symptoms, and could 16 
perhaps account for the differences in efficacy observed with others using B. lactis strains.  17 
Previous studies in chronic constipation have shown that not all treatments work for all pathophysiologies 18 
of constipation, likely due to the different underlying mechanisms involved 41. The absence of severe 19 
proctological and evacuatory disorders in the present study was determined based on the participants’ 20 
reported medical history, rather than on diagnostic investigation, such as proctography. Therefore, the 21 
potential heterogeneity in the pathophysiology of the study population may have contributed to the lack 22 
of effect. 23 
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In line with the findings on the clinical outcomes, there were no significant differences or changes in the 1 
stool microbiota following the consumption of the probiotic. Of note, no differences were observed in 2 
Bifidobacterium concentrations; this is a surprising finding as the probiotic consumed belonged to the 3 
Bifidobacterium genus and, therefore, an increase in Bifidobacterium in the probiotic group was expected. 4 
The lack of an increase in bifidobacteria could be explained in several ways. Firstly, it is possible that, 5 
although there might have been an increase in the B. lactis strain concentration in the gut, this could have 6 
been accompanied by a simultaneous decrease in endogenous Bifidobacterium species, possibly due to 7 
out-competition. However, the current literature does not support this theory; previous studies that have 8 
investigated the effect of probiotics on the gut microbiota have shown increases in the species to which 9 
the probiotic belonged 6 7. Secondly, the fact that there was no increase in bifidobacteria in the probiotic 10 
group may suggest that this B. lactis specific probiotic strain did not survive through the GI tract, although 11 
strain survival in the faeces was not measured per se due to lack of a validated analytical method for the 12 
specific strain. Previous human studies that have administered other B. lactis strains have successfully 13 
confirmed the strain survival by measuring its stool concentration using culture methods and qPCR 6 42. 14 
Survival of the strain is considered a key requirement of probiotics and can be affected by several host 15 
and product-specific factors, such as age, diet and baseline microbiota composition. Probiotic survival can 16 
also be influenced by exposure to low pH conditions of the stomach and bile acids, which can be tested in 17 
vitro 43. In fact, the survival of the B. lactis strain used in this study has been tested and confirmed in vitro 18 
following simulated gastric and duodenal conditions. Baseline microbiota composition is also a crucial 19 
factor for the survival of probiotics due to competition for substrates and binding sites 44; it is, thus, 20 
possible that the probiotic provided in this study was out-competed by the gut microbiota and, hence, 21 
was not viable in the colon. However, the lack of effect of the probiotic on the stool microbiota is in 22 
agreement with the findings of a systematic review of seven RCTs, which investigated the effect of 23 
probiotic supplementation on the stool microbiota and revealed that probiotics had no effects on the 24 
stool microbiota composition in terms of α-diversity, richness, or evenness when compared to placebo 45. 25 
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Other limitations involve the formula of the probiotic, which has not been previously studied in chronic 1 
bowel disorders. A meta-analysis of Helicobacter pylori eradication by probiotics delivered in fermented 2 
milk products showed that efficacy was better than that of capsule/sachet-based bacteria-only 3 
preparations 46. This is also supported by animal studies that suggest that fermented milk might augment 4 
probiotic functionality when compared to water or saline carriers 47 48. Therefore, the fact that the B. lactis 5 
was delivered in the form of a powder in the current study could have limited the activity or survival of 6 
the probiotic and hence its efficacy. Additionally, the results of the microbiological analysis might not be 7 
representative of all stools passed by the participants throughout the study since participants provided 8 
only one stool sample per time point.  9 
There were no differences in SCFA concentrations between the probiotic and the placebo groups. Short-10 
chain fatty acids are produced via fermentation by colonic bacteria. This study showed that the microbiota 11 
remained stable throughout the intervention period and, therefore, the lack of effect on end-products of 12 
bacterial fermentation, including SCFA, is unsurprising. Moreover, determination of SCFA production is 13 
challenging because the majority are produced in the proximal colon and more than 95% are rapidly 14 
absorbed in that region (i.e. <5% of SCFA are present in faeces); therefore, SCFA concentrations are 15 
considerably higher in the proximal colon compared to the distal colon, and the majority are unlikely to 16 
be detected in faeces 49.  17 
Notably, the vast majority (92%) of the study population consisted of females, highlighting the fact that 18 
the findings of this study cannot be extrapolated to male members of the public. Further, the study 19 
population was recruited from the community and, therefore, the findings cannot be generalised to 20 
patients in primary, secondary or tertiary care. However, despite the limitations, there are considerable 21 
strengths which include the randomised, double-blind design, large sample size, and use of the 22 
established formal Rome III diagnostic criteria (modified) and validated outcome assessment tools. 23 
Furthermore, an objective measure, WGTT, was used to investigate the primary outcome. 24 
21 
 
Conclusion 1 
This study has demonstrated that a 4 week intervention of B. lactis NCC2818 did not result in greater 2 
reduction in WGTT, nor impact other constipation-related outcomes, such as stool frequency and stool 3 
consistency, in a strictly-defined population with chronic mild constipation. This is in contrast to previous 4 
studies that have demonstrated a beneficial effect of other B. lactis strains in chronic constipation. 5 
Furthermore, this strain did not result in differences or changes in stool microbiota, including 6 
Bifidobacteria concentrations, stool SCFA, stool pH and stool water content. Further studies are needed 7 
in order to establish which probiotic strains, if any, are the most efficacious for the management of chronic 8 
constipation.  9 
Registration number: NCT01874301 10 
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TABLES 1 
Table 1: Baseline characteristics of participants in the intention to treat population, presented by group. 2 
Characteristics 
Probiotic 
(N=37) 
Placebo 
(N=38) 
Age, years 35 (12) 31 (10) 
Females, n (%) 34 (92) 35 (92) 
Height, cm 165 (6) 166 (7) 
Weight, kg 63.9 (9.2) 62.7 (9.1) 
BMI, kg/m2 23.6 (3.1) 22.8 (2.6) 
Menstrual cycle, n (%)   
Mid-follicular 18 (49) 20 (53) 
Mid-luteal 9 (24) 9 (24) 
Post-menopausal 7 (19) 6 (16) 
Cleveland Clinic Constipation Score (CCCS) † 12.8 (3.4) 11.3 (3.0) 
SBMs† 3.5 (1.4) 3.7 (2.1) 
Stool consistency (Bristol Stool Form Scale)‡ 2.8 (0.9) 2.9 (1.0) 
Hospital Anxiety and Depression Score (HADS) † 7.6 (6.8) 7.8 (6.0) 
Fibre intake, g/d 13.2 (2.6) 14.2 (2.3) 
Data are mean (SD), unless stated. 3 
†Numbers in each group: n=37 probiotic; n=37 placebo 4 
‡ Numbers in each group: n=36 probiotic; n=38 placebo 5 
 6 
 7 
 8 
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Table 2: Whole gut transit time (WGTT) and regionals gut transit time (in hours) in the intention to treat 1 
population. 2 
Outcome in hours 
Probiotic 
(N=37) 
Placebo 
(N=38) 
P value n Mean (SD) n Mean (SD) 
WGTT      
Baseline 37 81 (38) 38 72 (30) 0.242 
Mid-intervention (week 2) 36 69 (38) 36 61 (34) 0.930 
End of intervention (week 4)  35 58 (41) 34 63 (35) 0.062 
Δ in WGTT from baseline      
To mid- intervention (week 2) 36 -12 (33) 36 -13 (34) 0.863 
To end of intervention (week 4) 35 -20 (33) 34 -9 (34) 0.103 
Left colonic transit time      
Baseline 37 30 (26) 38 22 (17) 0.116 
Mid-intervention (week 2) 36 24 (21) 36 20 (13) 0.741 
End of intervention (week 4) 35 21 (22) 34 21 (20) 0.146 
Δ in left colonic transit time from baseline      
To mid- intervention (week 2) 36 -4 (14) 36 -4 (14) 0.839 
To end of intervention (week 4) 35 -5 (20) 34 -1 (21) 0.437 
Right colonic transit time      
Baseline 37 20 (15) 38 22 (10) 0.552 
Mid-intervention (week 2) 36 22 (19) 36 17 (13) 0.577 
End of intervention (week 4) 35 20 (17) 34 20 (11) 0.456 
Δ in right colonic transit time from baseline      
To mid- intervention (week 2) 36 1 (18) 36 -4 (18) 0.189 
To end of intervention (week 4) 35 -3 (14) 34 -3 (15) 0.954 
Rectosigmoid transit time      
Baseline 37 31 (20) 38 28 (18) 0.528 
Mid-intervention (week 2) 36 23 (18) 36 24 (18) 0.525 
End of intervention (week 4) 35 18 (16) 34 22 (19) 0.245 
Δ in rectosigmoid transit time from baseline      
To mid- intervention (week 2) 36 -7 (19) 36 -6 (19) 0.686 
To end of intervention (week 4) 35 -11 (17) 34 -6 (17) 0.134 
N: Number of participants in groups, n: Number of participants with available data. All p values are obtained from ANCOVA test(s) adjusted for 3 
covariates (baseline values, stage of menstrual cycle), except for the p value for baseline data, which is obtained from independent t-test(s). For 4 
the primary outcome (Δ in WGTT from baseline at mid-intervention), a P value of <0.0468 was considered statistically significant. 5 
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Table 3: Stool frequency, stool consistency, and gut symptoms in the intention to treat population. 1 
Outcome 
Probiotic 
(N=37) 
Placebo 
(N=38) 
P value n Mean (SD) n Mean (SD) 
Stool frequency and consistency      
Total bowel movements (TBM)/week      
 Baseline 36 3.6 (1.3) 38 4.1 (2.2) 0.273 
 Mid-intervention (week 2) 35 4.2 (1.9) 37 4.7 (3.2) 0.810 
 End of intervention (week 4)  36 4.5 (2.0) 37 4.8(2.8) 0.879 
Δ in TBM/week from baseline      
 To mid- intervention (week 2) 34 0.4 (2.3) 37 0.5 (2.4) 0.836 
 To end of intervention (week 4)  35 0.7 (2.4) 37 0.6 (2.4) 0.831 
Spontaneous bowel movements (SBM)/week      
 Baseline 36 3.5 (1.4) 38 3.7 (2.1) 0.710 
 Mid-intervention (week 2) 34 3.9 (1.9) 37 4.7 (4.0) 0.853 
 End of intervention (week 4)  35 4.5 (1.7) 37 4.8 (3.4) 0.857 
Δ in SBM/week from baseline      
 To mid- intervention (week 2) 33 0.3 (2.3) 37 0.5 (2.4) 0.712 
 To end of intervention (week 4)  35 0.6 (2.4) 37 0.8 (2.4) 0.638 
Complete spontaneous bowel movements (CSBM)/week      
 Baseline 32 2.2 (1.1) 32 2.7 (1.3) 0.105 
 Mid-intervention (week 2) 25 3.1 (1.4) 29 2.8 (1.5) 0.635 
 End of intervention (week 4)  27 3.3 (1.6) 31 3.5 (1.4) 0.685 
Δ in CSBM/week from baseline      
 To mid- intervention (week 2) 23 0.4 (1.4) 28 0.0 (1.6) 0.351 
 To end of intervention (week 4)  27 0.9 (0.4) 28 1.0 (1.6) 0.868 
Stool consistency      
 Baseline 36 2.8 (0.9) 38 2.9 (1.0) 0.695 
 Mid-intervention (week 2) 35 2.8 (1.1) 37 2.8 (1.1) 0.808 
 End of intervention (week 4)  36 2.9 (1.0) 37 2.9 (1.1) 1.174 
Δ in stool consistency from baseline      
 To mid- intervention (week 2) 34 -0.1 (1.2) 37 -0.1 (1.2) 0.8476 
 To end of intervention (week 4)  35 0.1 (1.2) 37 0.0 (1.2) 0.9364 
Gut symptoms      
GI tolerance      
Baseline 37 1.7 (0.7) 32 1.8 (0.7) 0.555 
Mid-intervention (week 2) 34 1.6 (0.7) 33 1.5 (0.5) 0.548 
End of intervention (week 4)  32 1.5 (0.7) 33 1.4 (0.5) 0.863 
Δ in GI tolerance from baseline      
 To mid- intervention (week 2) 34 -0.2 (0.6) 29 0.4 (0.5) 0.136 
To end of intervention (week 4)  32 -0.4 (0.6) 27 -0.6 (0.5) 0.151 
Bloating      
Baseline 37 5.8 (2.5) 37 5.0 (2.6) 0.983 
 Mid-intervention (week 2) 36 4.1 (2.5) 36 3.9 (2.7) 0.146 
 End of intervention (week 4)  36 4.1 (2.5) 36 3.8 (2.8) 0.782 
Δ in bloating from baseline      
 To mid- intervention (week 2) 36 -1.3 (2.4) 35 -0.9 (2.4) 0.466 
 To end of intervention (week 4)  36 -1.7 (2.4) 35 -1.5 (2.4) 0.704 
N: Number of participants in groups, n: Number of participants with available data. All p values are obtained from ANCOVA test(s) adjusted for 2 
covariates (baseline values, stage of menstrual cycle), except for the p value for baseline data, which is obtained from independent t-test(s).  3 
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Table 4: Constipation-related outcomes, including the Patient Assessment of Constipation Symptoms 1 
(PAC-SYM), Patient Assessment of Constipation Quality of Life (PAC-QoL), Cleveland Clinic Constipation 2 
Score (CCCS), and Global Constipation Symptom Score (GCSS) in the intention to treat population. 3 
Outcome 
Probiotic 
(N=37) 
Placebo 
(N=38) 
P value n Mean (SD) n Mean (SD) 
PAC-SYM global score      
Baseline 37 1.4 (0.6) 38 1.3 (0.7) 0.522 
Mid-intervention (week 2) 36 1.0 (0.6) 36 1.0 (0.6) 0.831 
End of intervention (week 4) 36 0.9 (0.6) 36 0.9 (0.6) 0.812 
Follow-up (week 8) 35 1.1 (0.7) 34 1.0 (0.7) 0.372 
Δ in PAC-SYM global score from baseline      
To mid- intervention (week 2) 36 -0.1 (0.6) 36 -0.0 (0.6) 0.474 
To end of intervention (week 4) 36 -0.3 (0.6) 36 -0.2 (0.6) 0.780 
To follow-up (week 8) 35 -0.1 (0.6) 34 -0.1 (0.6) 0.907 
PAC-QoL global score      
Baseline 37 1.1 (0.5) 38 1.0 (0.4) 0.178 
Mid-intervention (week 2) 36 1.0 (0.4) 36 0.8 (0.3) 0.606 
End of intervention (week 4) 36 0.9 (0.3) 36 0.9 (0.4) 0.449 
Follow-up (week 8) 35 0.9 (0.5) 33 0.8 (0.3) 0.685 
Δ in PAC-QoL Global from baseline      
To mid- intervention (week 2) 36 -0.1 (0.0) 36 -0.1 (0.0) 0.836 
To end of intervention (week 4) 36 -0.2 (0.6) 36 -0.1 (0.6) 0.315 
To follow-up (week 8) 35 -0.2 (0.6) 33 -0.2 (0.6) 0.977 
Cleveland Clinic Constipation Score (CCCS)      
 Baseline 37 12.8 (3.4) 37 11.3 (3.0) 0.999 
 Mid-intervention (week 2) 36 10.2 (4.0) 36 10.1 (3.2) 0.588 
 End of intervention (week 4)  36 10.2 (3.5) 36 9.7 (4.0) 0.861 
Follow-up (week 8) 35 10.3 (3.7) 33 10.1 (3.3) 0.670 
Δ in CCCS from baseline from baseline      
 To mid- intervention (week 2) 36 -2.4 (3.0) 35 -1.2 (3.0) 0.091 
 To end of intervention (week 4)  36 -2.3 (3.6) 35 -1.7 (4.1) 0.494 
To follow-up (week 8) 35 -2.2 (3.5) 32 -1.3 (3.4) 0.205 
Global Constipation Symptom Score      
 Baseline 37 0.1 (0.5) 37 -0.1 (0.4) 0.898 
 To mid- intervention (week 2) 36 0.7 (0.9) 36 0.7 (0.8) 0.500 
 To end of intervention (week 4)  36 0.9 (1.2) 36 0.8 (1.1) 0.653 
To follow-up (week 8) 35 0.8 (1.0) 33 0.6 (0.7) 0.813 
Δ in GCSS from baseline      
To mid-intervention (week 2) 36 0.8 (1.0) 36 0.7 (1.0) 0.768 
To end of intervention (week 4)  36 0.9 (1.3) 36 0.9 (1.3) 0.952 
To follow-up (week 8) 35 0.8 (1.0) 33 0.6 (1.0) 0.497 
N: Number of participants in groups, n: Number of participants with available data. All p values are obtained from ANCOVA test(s) adjusted for 4 
covariates (baseline values, stage of menstrual cycle), except for the p value for baseline data, which is obtained from independent t-test(s). 5 
PAC-SYM and PAC-QoL subscores can be found in Supporting Material Tables 1 and 2, respectively. 6 
30 
 
Table 5: Stool microbiota concentrations, short-chain fatty acids concentrations, pH and water content 
at baseline, mid- and end of intervention under the intention to treat analysis. 
 
Time point 
Probiotic  Placebo  P 
value*  n Descriptive  n Descriptive  
Microbiota concentrations (log10/g dry faeces), median (IQR) 
All bacteria Baseline 27 11.3 (0.5) 25 11.1 (1.0) 0.848 
Mid-intervention (week 2) 23 11.2 (0.5) 25 11.3 (1.1) 0.828 
End of intervention (week 4) 22 11.1 (0.9) 24 11.2 (0.7) 0.860 
Bifidobacterium spp. Baseline 26 9.4 (0.7) 23 9.5 (0.3) 0.548 
 Mid-intervention (week 2) 23 9.6 (0.4) 25 9.4 (1.8) 0.942 
 End of intervention (week 4) 21 9.5 (0.3) 24 9.4 (1.0) 0.509 
Bacteroides ssp. Baseline 27 10.1 (0.6) 25 10.1 (0.6) 0.805 
Mid-intervention (week 2) 23 10.1 (0.8) 25 10.3 (1.4) 0.893 
End of intervention (week 4) 22 10.1 (0.9) 24 10.1 (0.8) 0.895 
Prevotella ssp. Baseline 24 7.8 (2.0) 23 7.9 (2.1) 0.983 
 Mid-intervention (week 2) 20 8.6 (1.9) 24 8.1 (1.3) 0.077 
 End of intervention (week 4) 19 8.5 (2.5) 22 8.2 (0.9) 0.433 
Lachnospiraceae Baseline 27 10.0 (0.7) 24 9.8 (1.0) 0.850 
Mid-intervention (week 2) 23 10.0 (0.7) 25 9.7 (1.6) 0.926 
End of intervention (week 4) 22 10.0 (1.1) 24 10.0 (0.8) 0.582 
Roseburia ssp. Baseline 27 9.7 (1.8) 25 9.0 (1.3) 0.819 
 Mid-intervention (week 2) 23 9.1 (1.2) 25 9.6 (1.7) 0.380 
 End of intervention (week 4) 22 9.2 (1.3) 24 9.4 (0.9) 0.391 
F. prausnitzii Baseline 27 9.9 (0.7) 25 9.6 (0.8) 0.680 
 Mid-intervention (week 2) 23 10.1 (0.7) 25 9.5 (1.2) 0.415 
 End of intervention (week 4) 22 9.9 (0.7) 23 9.8 (0.7) 0.427 
Archaea Baseline 20 8.6 (2.0) 13 9.2 (1.0) 0.181 
 Mid-intervention (week 2) 11 8.5 (1.8) 18 8.6 (0.7) 0.611 
 End of intervention (week 4) 12 8.4 (1.6) 14 9.0 (0.7) 0.820 
Short-chain fatty acids (μmol/g dry faeces), mean (SD) 
P 
value† 
Total SCFA Baseline 25 374.2 (288.7) 24 294.8 (149.1) 0.238 
 Mid-intervention (week 2) 18 357.1 (273.1) 20 316.7 (189.6) 0.853 
 End of intervention (week 4) 16 367.0 (210.8) 18 407.7 (330.3) 0.501 
Acetate Baseline 25 206.7 (165.9) 24 157.7 (75.0) 0.195 
 Mid-intervention (week 2) 18 197.8 (150.7) 20 176.2 (103.9) 0.913 
 End of intervention (week 4) 16 209.7 (124.9) 18 228.3 (188.2) 0.625 
Propionate Baseline 25 65.6 (56.0) 24 52.6 (31.1) 0.328 
 Mid-intervention (week 2) 18 68.5 (67.4) 20 56.0 (37.2) 0.915 
 End of intervention (week 4) 16 67.1 (48.2) 18 72.3 (62.0) 0.474 
Butyrate Baseline 25 67.1 (61.2) 24 50.1 (32.8) 0.259 
 Mid-intervention (week 2) 18 56.6 (53.4) 20 51.4 (40.5) 0.618 
 End of intervention (week 4) 16 61.0 (41.2) 18 76.0 (83.4) 0.308 
Isobutyrate Baseline 25 10.6 (6.6) 24 10.1 (5.3) 0.774 
 Mid-intervention (week 2) 18 10.6 (5.0) 20 9.7 (4.0) 0.866 
 End of intervention (week 4) 16 8.9 (2.9) 18 9.2 (4.4) 0.590 
Valerate Baseline 25 9.0 (5.6) 24 10.1 (7.3) 0.589 
 Mid-intervention (week 2) 18 8.6 (4.2) 20 9.8 (8.2) 0.171 
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Time point 
Probiotic  Placebo  P 
value*  n Descriptive  n Descriptive  
 End of intervention (week 4) 16 8.2 (3.3) 18 8.9 (5.9) 0.409 
Isovalerate Baseline 25 15.0 (8.6) 24 14.5 (7.9) 0.835 
 Mid-intervention (week 2) 18 15.0 (6.8) 20 13.5 (4.9) 0.780 
 End of intervention (week 4) 16 12.1 (3.5) 18 13.1 (6.6) 0.433 
Stool pH, mean (SD) Baseline 19 6.9 (0.4) 19 6.9 (0.2) 0.860 
 Mid-intervention (week 2) 12 7.2 (0.6) 12 7.0 (0.5) 0.678 
 End of intervention (week 4) 10 7.2 (0.4) 9 6.7 (0.7) 0.180 
Water content (%), Baseline 22 68.7 (8.2) 23 64.7 (5.4) 0.062 
mean (SD) Mid-intervention (week 2) 17 67.7 (6.3) 17 64.8 (4.2) 0.339 
 End of intervention (week 4) 4 70.8 (8.0) 14 67.9 (7.1) 0.332 
*Mann-Whitney p value, †ANCOVA p value using baseline values as covariate, except for the p value for baseline data, which is 
obtained from independent t-test(s). 
  
32 
 
FIGURE LEGEND 
Figure 1: The CONSORT diagram 
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